BackSCIENCE_HEALTH
SMA patients seek nationwide access to generic Risdiplam under NPRD
SMA patients and guardians have written to Prime Minister Narendra Modi seeking urgent intervention to ensure nationwide access to generic Risdiplam under the NPRD. The move emphasizes SMA as a time-sensitive, life-limiting condition where delayed treatment can cause irreversible deterioration. The article notes an earlier publication timestamp of May 2, 2026 at 07:13 pm IST.
Why It Matters
Access to treatment under NPRD is time-sensitive for SMA, and this request could influence policy and funding for rare diseases in India.
Timeline
2 Events
SMA families write to Prime Minister Modi seeking access to generic Risdiplam under NPRD
May 3, 2026
Persons living with Spinal Muscular Atrophy (SMA), and parents of minor persons living with the condition, have written to Prime Minister Narendra Modi seeking his urgent intervention to ensure nationwide access to generic Risdiplam under the National Policy for Rare Diseases (NPRD).
May 2, 2026 publication timestamp noted
May 2, 2026
The article notes it was published on May 02, 2026 at 07:13 pm IST.